Zevra Therapeutics, Inc.
ZVRA
$8.43
$0.4856.11%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 12.04M | 3.70M | 4.45M | 3.43M | 12.92M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 12.04M | 3.70M | 4.45M | 3.43M | 12.92M |
| Cost of Revenue | 1.37M | 2.30M | 3.57M | 175.00K | 1.23M |
| Gross Profit | 10.68M | 1.39M | 876.00K | 3.25M | 11.69M |
| SG&A Expenses | 16.18M | 16.21M | 12.60M | 9.93M | 15.43M |
| Depreciation & Amortization | 1.62M | 1.55M | 1.55M | 1.53M | 772.00K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 27.46M | 31.00M | 28.24M | 23.91M | 28.08M |
| Operating Income | -15.42M | -27.31M | -23.80M | -20.49M | -15.16M |
| Income Before Tax | -20.37M | -33.23M | -19.86M | -16.69M | -19.89M |
| Income Tax Expenses | 15.37M | -- | 70.00K | -70.00K | -- |
| Earnings from Continuing Operations | -35.74M | -33.23M | -19.93M | -16.62M | -19.89M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -35.74M | -33.23M | -19.93M | -16.62M | -19.89M |
| EBIT | -15.42M | -27.31M | -23.80M | -20.49M | -15.16M |
| EBITDA | -13.77M | -25.69M | -22.23M | -18.92M | -14.37M |
| EPS Basic | -0.67 | -0.70 | -0.48 | -0.40 | -0.51 |
| Normalized Basic EPS | -0.24 | -0.44 | -0.30 | -0.25 | -0.32 |
| EPS Diluted | -0.67 | -0.70 | -0.48 | -0.40 | -0.51 |
| Normalized Diluted EPS | -0.24 | -0.44 | -0.30 | -0.25 | -0.32 |
| Average Basic Shares Outstanding | 53.47M | 47.81M | 41.90M | 41.78M | 38.72M |
| Average Diluted Shares Outstanding | 53.47M | 47.81M | 41.90M | 41.78M | 38.72M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
